Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Boutique Scans & Whole-Body MRI: A Clinical Review
Fishtown Medicine•11 min read
4.96 (124)

Boutique Scans & Whole-Body MRI: A Clinical Review

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 8, 2026
On This Page
  • Why has the full-body MRI grown so fast, and who benefits most?
  • What are the boutique imaging options compared?
  • What is the "incidentaloma" problem?
  • How do ACR White Paper rules, ACG 2024 guidelines, and non-invasive scans stop needless biopsies?
  • Guidance from the clinic
  • Actionable Steps for Informed Imaging
  • ✦Key Takeaways
  • Common Questions
  • How much does a boutique whole-body MRI cost?
  • Are boutique scans FDA-approved?
  • How do the whole-body MRI services differ from each other?
  • Should everyone get a whole-body MRI at age 40?
  • Can boutique scans replace standard cancer screening?
  • What is a PET-CT scan and why is it not a screening test?
  • Will my insurance cover any part of a boutique scan?
  • How long does the scan take?
  • Deep Questions
  • What is the incidentaloma rate on a whole-body MRI?
  • How does diffusion-weighted imaging detect tumors?
  • Why is whole-body MRI not great for lung cancer screening?
  • How do boutique scans compare to germline genetic testing?
  • What is the role of pericoronary fat attenuation in boutique cardiac imaging?
  • How do you advise patients with a history of anxiety about imaging decisions?
  • What is the difference between a boutique screening MRI and a hospital MRI?
  • How do you handle a small pancreatic cyst found on a screening MRI?
  • What is the role of contrast-enhanced ultrasound (CEUS) in triaging incidentalomas?
  • Should I get a thyroid ultrasound if my MRI or CT mentions a small thyroid nodule?
  • How does Fishtown Medicine integrate boutique scan results into the chart?
  • Why does Fishtown Medicine often recommend Galleri before or alongside a full-body MRI?
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

Boutique whole-body screening services use MRI to look for cancer and structural disease without radiation. Across 18,043 healthy adults (Ahsan JGIM 2026; Martins da Fonseca Eur Radiol 2026; Kwee 2019), scanning 1,000 asymptomatic people flags ~780 with an abnormality, ~320 with a critical or indeterminate finding, and ~150 with an actionable non-malignant finding (triggering ~86 follow-up workups and ~31 procedures) while finding cancer in ~14 to 16 people (1.4% to 1.57%) with zero randomized mortality proof (Cochrane 2026). We do not sell these scans; we help you decide whether one fits your hereditary/familial risk before you spend the money, and we apply ACR White Paper rules and non-invasive tie-breakers (CEUS, Eovist, chemical-shift MRI) so benign cysts never trigger needless biopsies.

TL;DR: Scanning 1,000 healthy adults with a commercial whole-body MRI flags about 780 people with an abnormality and 320 with an unclear spot, while finding true cancer in 14 to 16 people (about 1.5%).

  1. Match the scan to your personal risk: Whole-body MRI has no trial proof that it lowers deaths in average-risk adults, whereas cancer guidelines endorse yearly scans for high-risk gene carriers like Li-Fraumeni (where cancer yield is 7%).
  2. Check the 4 instant all-clear rules first: Once we confirm you have no prior cancer, immune suppression, or liver disease, four common findings need zero follow-up and zero biopsy: (1) non-cystic lung nodules under 6 mm in a low-risk adult, (2) simple liver cysts, hemangiomas, focal nodular hyperplasia, or smooth spots under 1 cm, (3) Bosniak I and II kidney cysts, and (4) CT or MRI thyroid spots under 1.0 cm (under age 35) or under 1.5 cm (age 35 and up).
  3. Use non-invasive tie-breaker scans before any needle: When a 1 to 2 cm spot looks unclear, contrast ultrasound (CEUS), gadoxetate liver MRI, or chemical-shift adrenal MRI settles 90% to 95% of cases without a biopsy.

A 45-year-old founder in Grad Hospital forwarded me his $2,499 commercial whole-body scan report at 4:45 PM on a Friday because it flagged four separate findings: a 4 mm right lower lobe lung nodule, a 1.1 cm liver hemangioma, a 1.8 cm thin-walled kidney cyst, and a 9 mm thyroid cyst. The report listed four specialist referral recommendations. After confirming he had no prior cancer, liver disease, or smoking risk, we pulled his images onto my screen and walked through the radiology society rules one organ at a time. His 4 mm lung nodule carried the same risk as having no nodule at all, his liver hemangioma and Bosniak I kidney cyst needed zero follow-up at any size, and his 9 mm thyroid cyst needed no biopsy. In thirty minutes, four scary specialist referrals became zero biopsies and a quiet weekend with his family.

Why has the full-body MRI grown so fast, and who benefits most?

Faster magnets and AI reconstruction let clinics image head to pelvis in 60 minutes without radiation. That is valuable for high-risk gene carriers (Li-Fraumeni TP53, Lynch, BRCA1/2) and complex family trees, while in average-risk adults the same sensitivity flags benign quirks in 78% to 95% of people (Zugni 2020; Ahsan 2026).

How testing works here

Dr. Ash orders this the same way he orders everything else, as part of primary care, so it is not something you can buy from us by itself. A number with nobody to read it against the rest of your picture is how most people end up with a result sitting in a portal and no idea what to do next.

What that looks like from your side is straightforward. The lab or imaging center bills you directly, at their price, with nothing added by us. Dr. Ash sends the order, reads the result next to your history and your other labs, and turns it into a plan you leave with. If there is something specific you want measured, that is a good thing to say up front.

Tell Dr. Ash what you want to find out

A mouthwash invented a disease is the clearest history of how commercial demand is built, and it is worth reading before buying any scan on your own. For patients with genetic risks or a strong family history of cancer, whole-body diffusion MRI can be a thoughtful part of a precision prevention plan when your physician applies strict follow-up rules so benign cysts do not lead to unnecessary procedures.

What are the boutique imaging options compared?

Boutique imaging options compared head-to-head:

ServicePrimary ClaimProsCons
Full-Body MRI (MRI-DWI)Early cancer and aneurysm detection.No radiation, high tissue detail.High cost ($1,500 to $2,500), high incidental finding rate.
Liquid Biopsy (Galleri)Multi-cancer early detection via blood.Simple draw, high specificity.May miss very early small tumors.
PET-CT ScansMetabolic activity of cancer cells.Finds active growing tumors.High radiation, not used for screening healthy adults.
Body Composition (DEXA)Fat vs. muscle mass.Gold standard for metabolic health.Low cost, high clinical value.
Cleerly CCTACoronary plaque phenotyping.Quantifies soft and calcified plaque.Targeted to heart only, uses radiation.

What is the "incidentaloma" problem?

Across pooled reviews of over 18,000 healthy adults (Kwee & Kwee 2019, Ahsan et al. 2026, Martins da Fonseca et al. 2026), scanning 1,000 healthy adults flags about 780 with an abnormal finding, 320 with a serious or unclear finding, and 150 with a non-cancer finding (leading to 86 follow-up scans or labs and 31 procedures), while true cancer is found in 14 to 16 scans (1.4% to 1.57%).

Whole-Body MRI Incidentalomas: The 18,043-Scan Funnel, ACR Safe Cutoffs, Thyroid & Pancreas Rules, and Non-Invasive Tie-Breakers

The incidentaloma cascade is the biggest risk of broad scans in average-risk adults. As a 2026 Cochrane review and a JAMA editorial by Davenport and Reeder point out, no randomized trial has shown that whole-body MRI screening cuts deaths or illness in the general public. By contrast, NCCN 2026 guidelines recommend yearly whole-body MRI for hereditary syndromes like Li-Fraumeni (TP53), where cancer yield is about 7% (versus 1.5% in the general public).

Four cohort findings show why unguided scans trigger so much follow-up testing:

  • Unclear ONCO-RADS spots and false alarms: In Kwee and Kwee's review of 5,373 adults, 32.1% of screened adults had a serious or unclear finding and 16.0% of verified findings were false positives. In a 2026 ONCO-RADS study by Ali and colleagues, 42.2% had an ONCO-RADS 3 or higher spot (nearly all unclear Category 3) while true cancer was 0.9%.
  • The 21,651-person pancreatic cyst cascade: In the largest screening MRI study to date (Wong et al., JAMA Network Open 2026), 7.0% of healthy adults had incidental pancreatic cysts (rising to 20.8% at age 80 and up). Only 0.08% had cysts larger than 3 cm, yet about 1,500 healthy people entered years of scan follow-up.
  • Higher outpatient costs and benign biopsies: In Germany's SHIP study, sharing whole-body MRI findings raised 2-year outpatient costs by 11.6% (Schmidt BMJ Open 2022) and raised benign biopsies by 39% (rate ratio 1.39, Richter Eur J Epidemiol 2020).
  • False reassurance: A normal whole-body MRI does not rule out common cancers. In a 576-person screening study by Basar and colleagues, 2.8% had false-negative scans, including missed colon, breast, and thyroid cancers.

How do ACR White Paper rules, ACG 2024 guidelines, and non-invasive scans stop needless biopsies?

When a boutique Prenuvo or Ezra report arrives in your inbox with 3 or 4 flagged spots, we first check that you have no known cancer, immune suppression, chronic liver disease, or warning symptoms (and that a chest CT was not ordered for smoker lung-cancer screening, which uses Lung-RADS). Next, we apply two layers of evidence before anyone touches a biopsy needle:

  1. Whole-scan ONCO-RADS scoring (Petralia et al., Radiology 2021): ONCO-RADS grades findings from 1 (normal) to 5 (highly likely cancer). In 2,064 screened adults (Hu et al. 2024), cancer was confirmed in only 0.1% of Category 2 scans and 5.4% of Category 3 scans, versus 42.9% of Category 4 and 75.0% of Category 5 scans.
  2. Organ-specific Fleischner 2017, ACG 2024, Bosniak v2019, and ACR TI-RADS cutoffs:
    • Lung nodules (2017 Fleischner Society and SUMMIT Study, Creamer Thorax 2025): About 95% of incidental lung nodules in healthy adults aged 35 and up are benign old scars or lymph nodes. A single or multiple dense (non-cystic) nodule under 6 mm (under 100 mm3) in a low-risk adult carries under 1% cancer risk (0.5% in NLST) and the same cancer risk as having no nodule at all (0.88% vs. 0.77% in SUMMIT, n = 11,355). That means zero routine follow-up CT (in high-risk patients, an optional 12-month CT is used only if the spot is upper-lobe or spiky). Dense nodules measuring 6 to 8 mm (1% to 2% risk) get a CT at 6 to 12 months (any nodule stable for 2 full years is benign). Pure ground-glass nodules under 6 mm need no follow-up, and nodules over 8 mm (over 250 mm3) get a 3-month CT, PET/CT, or lung specialist review.
    • Liver (ACG 2024 Guideline, Frenette et al. and ACR 2017 Gore et al.): In low-risk adults without cirrhosis or known cancer, over 95% of liver spots are benign. Under ACG 2024 rules, simple cysts (any size), hemangiomas (any size, birth control pills can continue, and biopsy is avoided), confirmed focal nodular hyperplasia (FNH, zero cancer risk, pregnancy safe), and smooth spots under 1.0 cm need zero follow-up. By contrast, liver adenomas require stopping estrogen pills and weight loss (women with adenomas under 5 cm get MRI every 6 months for 2 years then yearly; surgery if 5 cm or larger or at any size in men). For unclear spots 1.0 cm or larger, multiphasic MRI with gadoxetate (Eovist) solves up to 95% without a needle (94% to 97% of FNH glow bright on the liver phase with 93.9% sensitivity and 95.3% specificity, Suh 2015, noting some inflammatory adenomas also glow, Furumaya 2024). Contrast-enhanced ultrasound (CEUS) reaches 97.8% sensitivity for benign liver spots.
    • Kidney (Bosniak v2019, Silverman 2019, McGrath 2025 and AUA 2021): Simple kidney cysts show up in over half of adults past 70. Plain ultrasound reliably calls Bosniak I (smooth wall 2 mm or thinner) and Bosniak II (1 to 3 thin dividing walls, any calcium, or a dense spot 70 HU or higher on non-contrast CT, which has a 99.9%+ chance of being a benign dense cyst). Both Bosniak I and II need zero follow-up (cyst growth alone is not cancer). Bosniak IIF (3 mm wall or 4+ thin walls) gets imaging at 6 months, 12 months, then yearly to 5 years (0 of 246 upgraded at 6 months in Shen 2023; only 2% show cancer on imaging follow-up). Contrast ultrasound (CEUS) rules out cyst-wall blood flow with 100% negative predictive value and zero kidney risk (Desai Radiographics 2026). Bosniak III (only 10.3% aggressive cells, Tse Radiology 2026) and Bosniak IV go to urology for active watching or partial removal.
    • Adrenal (ACR 2021): Nodules under 1.0 cm need no workup. Any nodule measuring 10 HU or less on non-contrast CT or showing fat content on chemical-shift MRI (94% sensitivity and 95% specificity, Platzek 2019) is a benign fat-rich adenoma (0% cancer risk) and needs no follow-up.
    • Pancreas (ACR Pancreas White Paper): Simple cysts under 1.5 cm get calm MRI checks every 1 to 2 years (stopping at age 80). Immediate GI referral for endoscopic ultrasound (EUS) is reserved for cysts 3.0 cm or larger, enhancing wall nodules, or main duct widening 7 to 10 mm or more.
    • Thyroid (ACR 2015 White Paper, TI-RADS 2017 and Song Thyroid 2024): Across 6,272 patients with CT thyroid spots (Song 2024), cancer was 3.9% overall (0.1% under 1 cm, 0% under 1.5 cm, and 1.8% across CT, ultrasound, and MRI spots in Willems Thyroid 2026). On CT or MRI, without abnormal lymph nodes or focal PET scan uptake (19% to 31% cancer risk), a thyroid spot does not need an ultrasound if it is under 1.0 cm (under age 35) or under 1.5 cm (age 35 and up). On ultrasound, TR1 (0 pts) and TR2 (2 pts, under 2% risk) need zero biopsy and zero follow-up. ACR TI-RADS biopsies only at 2.5 cm for TR3, 1.5 cm for TR4, or 1.0 cm for TR5 (stopping follow-up at 5 years if stable).

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can follow.

Start your intake
Incidental FindingZero Further Workup ("Stop" Rule)Calm Imaging SurveillanceReferral / Tissue Sampling
Solitary Lung Nodule (Fleischner 2017, age >= 35)< 6 mm (< 100 mm3), low risk (0.88% vs. 0.77% no-nodule risk, SUMMIT 2025); or pure ground-glass < 6 mm.6-8 mm: CT at 6-12 mo (± 18-24 mo); < 6 mm high risk: optional 12-mo CT; ground-glass >= 6 mm: 6-12 mo then q2y to 5 yr.> 8 mm (> 250 mm3): CT at 3 mo, FDG-PET/CT, or biopsy.
Liver Lesion (ACG 2024 & ACR 2017, low risk)Simple cyst (any size), confirmed hemangioma (any size, OCPs ok), confirmed FNH (any size), or smooth < 1 cm spot.Hepatocellular adenoma in women < 5 cm: stop OCPs/hormones + MRI q6m for 2 yr, then yearly.Indeterminate >= 1.0-1.5 cm: Multiphasic Gadoxetate MRI or CEUS first; adenoma in men (any size) or >= 5 cm -> surgery.
Renal Cyst (Bosniak v2019 & AUA 2021)Bosniak I (<= 2 mm wall) & Bosniak II (1-3 thin septa or homogeneous >= 70 HU unenhanced CT, > 99.9% benign).Bosniak IIF (3 mm wall or >= 4 thin septa): CT/MRI at 6 mo, 12 mo, then yearly to 5 yr (2% imaging progression).Bosniak III / IV: Urology referral for active surveillance (AUA 2021) or partial nephrectomy.
Thyroid Nodule (ACR 2015 & TI-RADS 2017)CT/MRI < 1.0 cm (age < 35) or < 1.5 cm (age >= 35) (0% cancer < 1.5 cm, Song 2024); or ultrasound TR1 / TR2.Ultrasound follow-up (stop at 5 yr if stable): TR3 >= 1.5 cm (1, 3, 5y), TR4 >= 1.0 cm (1, 2, 3, 5y), TR5 >= 0.5 cm (q1y-5y).Fine-Needle Biopsy (FNA): TR3 >= 2.5 cm, TR4 >= 1.5 cm, TR5 >= 1.0 cm, or any focal FDG-PET avid nodule (19%-31% risk).

Guidance from the clinic

Dr. Ash
"More data is not always better data. I recommend boutique scans selectively, for patients whose family history or genetic markers warrant a thorough defense. For most people, we get more leverage from high-resolution labs and metabolic optimization. If you already did a full-body scan and got a scary report, bring us the images before anyone schedules a biopsy."

Actionable Steps for Informed Imaging

Use these four triggers before or after booking a boutique scan:

  1. If you have not booked a scan yet -> check your family history and baseline labs first: Start with a genetic and family history review, ApoB, Lp(a), fasting insulin, and standard colon, breast, cervical, and skin screening. Do those before spending $2,000+ on a magnet.
  2. If your main worry is heart disease or belly fat -> pick CAC/CCTA and DEXA instead of a full-body MRI: Whole-body MRI is a poor tool for heart arteries. A $100 calcium score or $450 standard-read coronary CT angiogram paired with a $100 to $150 DEXA scan gives sharper answers for a fraction of the price.
  3. If you already have a Prenuvo or Ezra report flagging a cyst or nodule -> apply ACR size cutoffs and non-invasive tie-breakers (CEUS, chemical-shift MRI, or Gadoxetate MRI) before any biopsy: Upload your PDF and DICOM link. Most liver spots under 1.5 cm, Bosniak I and II kidney cysts, adrenal nodules under 1 cm, and thyroid spots under 1.5 cm (age 35+) need zero follow-up.
  4. If you have a strong multi-cancer family history -> compare clinical MRI-DWI and liquid biopsy first: We help you weigh whether a hospital full-body MRI protocol or a Galleri multi-cancer blood test fits your risk profile best.
✦

Key Takeaways

  1. Across 18,043 screened adults, whole-body MRI flags findings in 78% to 95% and triggers follow-up in 15% to 32%, while confirming cancer in 1.1% to 1.6%.
  2. ACR Incidental Findings White Paper rules safely clear liver spots under 1.5 cm, Bosniak I and II kidney cysts, adrenal adenomas under 1 cm (or 10 HU or less), and thyroid spots under 1.5 cm (at age 35+) without extra testing.
  3. Non-invasive problem-solving scans (Contrast Ultrasound CEUS, Gadoxetate liver MRI, and Chemical-Shift adrenal MRI) resolve ~90% of indeterminate spots without a needle biopsy.
  4. Targeted scans (CAC, CCTA, DEXA, low-dose lung CT for smokers) and Tier 1 cancer screens come before boutique whole-body scans.

A note on cost: any discount we negotiate on labs and imaging passes straight through to you, with no markup. Our affordable labs and imaging guide covers how the billing works.

Scientific References

  1. Kwee RM, Kwee TC. "Whole-Body MRI for Preventive Health Screening: A Systematic Review of the Literature." Journal of Magnetic Resonance Imaging. 2019;50(5):1489-1503. PubMed
  2. Zugni F, Padhani AR, Koh DM, et al. "Whole-Body Magnetic Resonance Imaging (WB-MRI) for Cancer Screening in Asymptomatic Subjects of the General Population: Review and Recommendations." Cancer Imaging. 2020;20(1):34. PubMed
  3. Ahsan MD, Frontera N, Gurram A, et al. "The Diagnostic Yield of Whole-Body MRI as a Multi-Disease Screening Modality: A Systematic Review and Meta-Analysis." Journal of General Internal Medicine. 2026. PubMed
  4. Petralia G, Koh DM, Attariwala R, et al. "Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening." Radiology. 2021;299(3):494-507. PubMed
  5. MacMahon H, Naidich DP, Goo JM, et al. "Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017." Radiology. 2017;284(1):228-243; and Creamer AW, Horst C, Verghese P, et al. (SUMMIT Study). Thorax. 2025;80(7):454-462.
  6. Frenette C, Mendiratta-Lala M, Salgia R, et al. "ACG Clinical Guideline: Focal Liver Lesions." American Journal of Gastroenterology. 2024;119(7):1235-1271; and Gore RM, Pickhardt PJ, Mortele KJ, et al. (ACR Liver White Paper). Journal of the American College of Radiology. 2017;14(11):1429-1437. PubMed
  7. Silverman SG, Pedrosa I, Ellis JH, et al. "Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment." Radiology. 2019;292(2):475-488; McGrath TA, Davenport MS, Silverman SG, et al. AJR American Journal of Roentgenology. 2025;224(3):e2432056; and Tse JR, Shen L, Shen J, et al. Radiology. 2026;318(2):e252431.
  8. Hoang JK, Langer JE, Middleton WD, et al. (ACR Incidental Thyroid Nodules). Journal of the American College of Radiology. 2015;12(2):143-150; Tessler FN, Middleton WD, Grant EG, et al. (ACR TI-RADS). Journal of the American College of Radiology. 2017;14(5):587-595; Song Z, Wu C, Fang J, et al. Thyroid. 2024;34(9):1113-1122; and Willems J, et al. Thyroid. 2026;36(1):56-65.
  9. Platzek I, Sieron D, Plodeck V, et al. "Chemical Shift Imaging for Evaluation of Adrenal Masses: A Systematic Review and Meta-Analysis." European Radiology. 2019;29(2):806-815. PubMed
  10. Wu M, Li L, Wang J, et al. "Contrast-Enhanced US for Characterization of Focal Liver Lesions: A Comprehensive Meta-Analysis." European Radiology. 2018;28(5):2077-2088. PubMed

Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.

Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all", the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, including if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

A boutique whole-body MRI costs about $1,500 to $2,500. Screening MRI centers do not take insurance and run on self-pay. HSA and FSA funds usually apply.
Boutique whole-body MRI scans use FDA-cleared scanners and software. The full-body screening service itself is not cleared as a general screening test, and no randomized trial has proven a mortality benefit in average-risk adults (Cochrane 2026).
Whole-body MRI services differ in coil hardware, scan time, and whether they report standardized ONCO-RADS scores (Petralia 2021). Some use custom coils and a 60-minute MRI-DWI protocol; others layer AI software onto faster 30-to-40-minute hospital machines.
Not everyone needs a whole-body MRI at age 40. The best candidates have a known gene mutation (such as Li-Fraumeni or Lynch syndrome), a strong family history of cancer, or a past cancer. For an average-risk 40-year-old, the chance of an incidentaloma (78% to 95%) is far higher than the chance of finding a tumor (1.1% to 1.6%).
Boutique scans cannot replace colonoscopies, mammograms, low-dose lung CT, or Pap smears. Those standard tests have decades of randomized trial proof. Boutique scans are an optional Tier 2 layer on top of proven screening.
A PET-CT scan pairs a CT scan with a sugar tracer to light up fast-growing cells. We never use it to screen healthy adults because it delivers high radiation (about 25 mSv) and creates too many false alarms. PET-CT is for staging known cancer.
Insurance does not pay for a boutique screening scan when you have no symptoms. If a boutique scan finds an indeterminate spot that truly needs a follow-up CEUS ultrasound or targeted organ MRI under ACR guidelines, Dr. Ash can order that diagnostic scan through your insurance.
The scan takes about 45 to 60 minutes inside the magnet. The full visit takes about 90 minutes. Results post in 1 to 2 weeks.

Deep-Dive Questions

In pooled analyses of asymptomatic adults (Zugni 2020, Kwee & Kwee 2019, Ahsan 2026), 78% to 95% of scans report an abnormal finding, 15% to 32% trigger follow-up workups, and 16% of verified findings turn out to be false positives, while confirmed cancer occurs in 1.1% to 1.6%.
Diffusion-weighted imaging (DWI) tracks how water moves inside tissue. Tumor cells pack tightly together, so water cannot move freely. Those spots light up bright on DWI maps without needing IV dye.
Whole-body MRI struggles with the lungs because air creates a weak MRI signal. Low-dose CT is the gold standard for current and former smokers who meet pack-year rules.
Genetics tells you what you are at risk for. Imaging checks whether a tumor is there today. We often start with a one-time gene panel so we know which organs need closer watching.
Pericoronary fat attenuation measures inflammation around the heart arteries on a cardiac CT. It belongs to dedicated heart imaging (CCTA), which whole-body MRI does not cover well.
If health worry runs high for you, we talk openly before booking a whole-body MRI. Waiting 6 months to recheck a harmless 8 mm cyst can feel miserable. Targeted tests often give better answers with far less stress.
A boutique screening MRI scans from head to pelvis in about an hour to look for broad issues. A targeted hospital MRI zooms in on one organ (such as a gadoxetate liver MRI, chemical-shift adrenal MRI, or multiparametric prostate MRI) with much higher resolution to solve an unclear finding without a biopsy.
Under the ACR Pancreatic Cyst White Paper (Gardner 2024), an incidental cyst under 1.5 cm with no high-risk features enters calm MRI surveillance (yearly for 5 years if under 65, or every 2 years if 65 to 79). Cysts 3.0 cm or larger, enhancing wall nodules, or main pancreatic duct widening 7 to 10 mm or more go directly to a GI specialist for endoscopic ultrasound (EUS).
Contrast-enhanced ultrasound (CEUS) uses tiny gas microbubbles to show live blood flow in a liver or kidney spot with zero radiation and zero kidney risk. Across 57 liver studies (Wu 2018), CEUS reaches 92% sensitivity and 87% specificity and cuts indeterminate liver diagnoses from 57% down to 6%.
Only if it crosses the ACR size trigger. Under the ACR Incidental Thyroid Nodule White Paper (Hoang 2015), a thyroid spot seen on MRI or CT without suspicious lymph nodes or local invasion needs no ultrasound if it is under 1.0 cm (under age 35) or under 1.5 cm (age 35+), unless it lights up on an FDG-PET scan (which carries a 19% to 31% cancer rate, Scappaticcio 2021; Coerts 2026). Across 6,272 CT thyroid incidentalomas (Song 2024), overall malignancy was 3.9%, with 0.1% malignancy below 1.0 cm and 0% below 1.5 cm. See what a thyroid nodule on a scan means for the full ACR TI-RADS biopsy thresholds.
We upload the full PDF and DICOM image files into your chart. Then we apply ONCO-RADS and the organ-specific ACR and ACG White Paper thresholds to separate harmless cysts from anything that needs action, and schedule any needed follow-up scan on a clear calendar.
We compare Galleri and whole-body MRI in high-risk adults for two reasons. First, Galleri can spot methylated tumor DNA signals from cancers that MRI misses early. Second, Galleri has a 99.5% specificity (a 0.5% false-positive rate), which spares you the 78% incidentaloma cascade.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Go beyond standard cancer screening. A Philadelphia primary care practice using liquid biopsies and whole-body MRI to find disease earlier.

Read Deep Dive
When to Order Imaging: How We Decide What's Worth Scanning

When to Order Imaging: How We Decide What's Worth Scanning

A Philadelphia internal medicine doctor on the framework for deciding when a scan is worth ordering, when it can do harm, and how to pick the right tool for the question.

Read Deep Dive
Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Standard cholesterol panels miss most heart attacks. See how a Philadelphia preventive cardiology approach uses ApoB, Lp(a), and modern imaging to catch risk early.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

If anything you read here raised a question, share it in your own words. Dr. Ash reads every intake personally, and you can text or email us anytime.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs